Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-08-18
2009-11-24
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S359100
Reexamination Certificate
active
07622492
ABSTRACT:
Provided herein are compounds of the formula (I):as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.
REFERENCES:
patent: 3047461 (1962-07-01), Hardy, Jr. et al.
patent: 2004/0122033 (2004-06-01), Nargund et al.
patent: 2004/0133011 (2004-07-01), Waddell et al.
patent: 2005/0137209 (2005-06-01), Oksenberg et al.
patent: 2005170939 (2005-06-01), None
patent: WO 0190090 (2001-11-01), None
patent: WO 0190091 (2001-11-01), None
patent: WO 0190092 (2001-11-01), None
patent: WO 0190093 (2001-11-01), None
patent: WO 0190094 (2001-11-01), None
patent: WO 02076435 (2002-10-01), None
patent: WO 03043999 (2003-05-01), None
patent: WO 03044000 (2003-05-01), None
patent: WO 03044009 (2003-05-01), None
patent: WO 03059267 (2003-07-01), None
patent: WO 03065983 (2003-08-01), None
patent: WO 03075660 (2003-09-01), None
patent: WO 03104207 (2003-12-01), None
patent: WO 03104208 (2003-12-01), None
patent: WO 2004011410 (2004-02-01), None
patent: WO 2004027047 (2004-04-01), None
patent: WO 2004033427 (2004-04-01), None
patent: WO 2004037251 (2004-05-01), None
patent: WO 2004041264 (2004-05-01), None
patent: WO 2004056744 (2004-07-01), None
patent: WO 2004056745 (2004-07-01), None
patent: WO 2004058741 (2004-07-01), None
patent: WO 2004065351 (2004-08-01), None
patent: WO 2004089367 (2004-10-01), None
patent: WO 2004089380 (2004-10-01), None
patent: WO 2004089415 (2004-10-01), None
patent: WO 2004089416 (2004-10-01), None
patent: WO 2004089470 (2004-10-01), None
patent: WO 2004089471 (2004-10-01), None
patent: WO 2004089896 (2004-10-01), None
patent: WO 2004097002 (2004-11-01), None
patent: WO 2004103980 (2004-12-01), None
patent: WO 2004106294 (2004-12-01), None
patent: WO 2004112779 (2004-12-01), None
patent: WO 2004112781 (2004-12-01), None
patent: WO 2004112782 (2004-12-01), None
patent: WO 2004112783 (2004-12-01), None
patent: WO 2004112784 (2004-12-01), None
patent: WO 2004112785 (2004-12-01), None
patent: WO 2004113310 (2004-12-01), None
patent: WO 2005016877 (2005-02-01), None
patent: WO 2005042513 (2005-05-01), None
patent: WO 2005044192 (2005-05-01), None
patent: WO 2005046685 (2005-05-01), None
patent: WO 2005047250 (2005-05-01), None
patent: WO 2005060963 (2005-07-01), None
Abstract JP2005170939.
R. A. De FronzoDrugs1999,58 Suppl. 1, 29.
S. E. InzucchiJAMA2002, 287, 360.
R. C. Turner et al.JAMA1999, 281, 2005.
M. Tadayyon and S. A. SmithExpert Opin. Investig. Drugs2003, 12, 307.
M. Salas J. J. and CaroAdv. Drug React. Tox. Rev. 2002, 21, 205-217.
E. S. Ford et al.JAMA2002, 287, 356.
Y. Kotolevtsev et al.Proc. Natl. Acad. Sci. USA1997, 94, 14924.
N. M. Morton et al.J. Biol. Chem. 2001, 276, 41293.
H. Masuzaki et al.Science, 2001, 294, 2166.
B. R. Walker et al.J. Clin. Endocrinol. Metab. 1995, 80, 3155.
R. C. Andrews et al.J. Clin. Enocrinol. Metab. 2003, 88, 285.
T. C. Sandeep et al.Proc. Natl. Acad. Sci USA2004, 101, 6734.
S. Diederich et al.Eur. J. Endocrinol. 2000, 142, 200.
R. A. S. Schweizer et al.Mol. Cell. Endocrinol. 2003, 212, 41.
H. Ansel et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at pp. 196.
H. Ansel et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at pp. 1456-1457.
Design of Prodrugs. Bundgaard H. ed. (Elsevier, 1985). H. Ansel et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at pp. 108-109.
Krogsgaard-Larsen, et. al., Textbook of Drug Design and Development (2d Ed. 1996) at pp. 152-191.
W. W. Shumway et al.J. Org. Chem. 2001, 66, 5832-5839.
H. Staudinger and S. SchotzChem. Ber. 1920, 53B, 1105-1124.
Chemical Abstracts 14:18286.
S. Nagai et al.Chem. Pharm. Bull. 1979, 27, 1764-1770.
H. Wahl,Ber. Dtsch. Chem. Ges. 1899, 32, 1987-1991.
A. R. Maguire et al.Bioorg Med. Chem. 2001, 9, 745-762.
Laboratoires Marinier FR 1.271.246 and FR 701.
G. H. Alt and J. P. ChuppTetrahedron Lett. 1970, 36, 3155-3158.
P. C. Guha and N. K. SeshadriengarChem. Ber. 1936, 69B, 1212-1218.
F. Ramirez and J. W. SargentJ. Am. Chem. Soc. 1955, 77, 6297-6306.
B. Jursic and N. BregantSynth. Commun. 1989, 19, 2087-2094.
C. Dardonville et al.New Journal of Chemistry1998, 22, 1421-1430.
P. Nair et al.Tetrahedron1960, 11, 140-147.
M. Wolter et al.Org. Letters2001, 3, 3803-3805.
A. Klapars et al.J. Am. Chem. Soc. 2001, 123, 7727-7729.
B. RengerSynthesis1985, 856-806.
G. M. CoppolaJ. Heterocycl. Chem. 1987, 24, 1249-1251.
A. GreinerSynthesis1989, 312-313.
T. Maruyama et al.J. Chem. Soc. Perkin Trans. I1995, 733-734.
S.-K. Kang et al.Synlett2002, 427-430.
J. H. M Lange et al.Tetrahedron Lett. 2002, 43, 1101-1104.
W. C ShakespeareTetrahedron Lett. 1999, 40, 2035-2038.
D. M. T. Chan et al.Tetrahedron Lett. 1998, 39, 2933-2936.
W. W. K. R. Mederski et al.Tetrahedron1999, 55, 12757-12770.
G. W. Kabalka and S. K. GuchhaitOrg. Lett. 2005, 5, 4129-4131.
O. V. Dyablo et al.Chem. Heterocycl. Compd. 2002, 38, 620-621.
N. J. Green et al.Bioorg. Med. Chem. 2003, 11, 2991-3013.
M. T. Makhija et al.Bioorg. Med. Chem. 2004, 12, 2317-2333.
M. van der Mey et al.J. Med. Chem. 2003, 46, 2008-2016.
R. West and H. F. StewartJ. Am. Chem. Soc. 1970, 92, 853-859.
M. Pal et al.J. Med. Chem. 2003, 46, 3975-3984.
E. W. ParnellJ. Chem. Soc. 1959, 2363-2365.
L. Ondi et al.Eur. J. Org. Chem. 2004, 3714-3718.
N. Guillot et al.Tetrahedron1990, 46, 3897-3908.
J. P. Demers and D. H. KlaubertTetrahedron Lett. 1987, 28, 4933-4934.
F. D. King and D. R. M. WaltonSynthesis1975, 738-739.
R. C. Larock, VCH Publishers, Inc. New York, 1989, p. 313.
R. C. Larock, VCH Publishers, Inc. New York, 1989, p. 322-393.
R. C. Larock, VCH Publishers, Inc. New York, 1989, p. 353-363.
R. C. Larock, VCH Publishers, Inc. New York, 1989, 381-382.
Advanced Organic Chemistry [J. March, 3rdEdition, John Wiley & Sons, Inc. New York, 1985], on pp. 382-384.
R. C. Larock, VCH Publishers, Inc. New York, 1989, p. 316-318.
R. C. Larock, VCH Publishers, Inc. New York, 1989, p. 345-346.
Advanced Organic Chemistry [J. March, 3Edition, John Wiley & Sons, Inc. New York, 1985], on p. 1155.
C. Glende et al.Mutation Res. 2002, 515, 15-38.
A. Fensome et al.; M. Gravel et al.J. Org. Chem2002, 67, 3-15.
D. Florentin et al.J. Heterocycl. Chem. 1976, 13, 1265-1272.
M. P. Groziak et al.J. Am. Chem. Soc. 1994, 116, 7597-7605.
W. Li et al.J. Org. Chem. 2002, 67, 5394-5397.
S. L. Gilat et al.Chem. Eur. J. 1995, 1, 275-284.
W. J. Dale et al.J. Org. Chem. 1962, 27, 2598-2603.
T. E. Jacks et al.Org. Proc. Res. Dev. 2004, 8, 201-212.
F. C. Fischer et al.Recl. Trav. Chim. Pays-Bas1974, 93, 21-24.
M. Takeshita et al.J. Org. Chem. 1998, 63, 6643-6649.
K. A. Jensen et al.Acta Chem Scand. 1968, 22, 1-50.
M.-F. Pinto et al.Synth. Commun. 2002, 32, 3603-3610.
N. Brosse et al.J. Org. Chem. 2000, 65, 4370.
H. HilpertTetrahedron2001, 57, 7675-7683.
N. I. Ghali et al.J. Org. Chem. 1981, 46, 5413-5414.
A. Koziara et al.Synth. Commun. 1995, 25, 3805-3812.
A. R. Maguire et al.Bioorg. Med. Chem. 2001, 9, 745-762.
Abstract XP002401736.
Banner Bruce Lester
Bilotta Joseph Anthony
Fotouhi Nader
Gillespie Paul
Goodnow, Jr. Robert Alan
Hoffmann-La Roche Inc.
Johnston George W.
Megerditchian Samuel H.
Saeed Kamal A
Tramaloni Dennis P.
LandOfFree
Pyrazolones as inhibitors of 11β-hydroxysteroid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolones as inhibitors of 11β-hydroxysteroid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolones as inhibitors of 11β-hydroxysteroid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4136079